Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2015

01-04-2015 | Research Article

A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

Authors: S. Hernández-Prieto, A. Romera, M. Ferrer, J. L. Subiza, J. A. López-Asenjo, J. R. Jarabo, A. M. Gómez, Elena M. Molina, J. Puente, J. L. González-Larriba, F. Hernando, B. Pérez-Villamil, E. Díaz-Rubio, J. Sanz-Ortega

Published in: Clinical and Translational Oncology | Issue 4/2015

Login to get access

Abstract

Purpose

To identify a novel system for scoring intratumoral immune response that can improve prognosis and therapy decisions in early stage non-small cell lung cancer (NSCLC).

Methods/patients

Eighty-four completely resected stage I/II NSCLC without adjuvant therapy were classified by expression profiling using whole genome microarrays. An external cohort of 162 tumors was used to validate the results. Immune cells present in tumor microenvironment were evaluated semiquantitatively by CD20, CD79, CD3, CD8, CD4 and CD57 immunostaining. Univariate and multivariate analyses of variables associated with recurrence-free survival were performed.

Results

Initial molecular classification identified three clusters, one with significantly better RFS. A reduced two-subgroup classification and a 50-gene predictor were built and validated in an external dataset: high and low risk of recurrence patients (HR = 3.44; p = 0.001). Analysis of the predictor´s genes showed that the vast majority were related to a B/plasma cell immune response overexpressed in the low-risk subgroup. The predictor includes genes coding for unique B lineage-specific genes, functional elements or other genes that, although non-restricted to this lineage, have strong influence on B-cell homeostasis. Immunostains confirmed increased B-cells in the low-risk subgroup. Gene signature (p < 0.0001) and CD20 (p < 0.05) were predictors for RFS, while CD79 and K-RAS mutations showed a tendency.

Conclusions

Favorable prognosis in completely resected NSCLC is determined by a B-cell-mediated immune response. It can be differently scored by a 50-gene expression profile or by CD20 immunostaining. That prognosis information not reflected by traditional classifications may become a new tool for determining individualized adjuvant therapies.
Appendix
Available only for authorised users
Literature
1.
2.
Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. The IASLC Lung cancer staging project: proposals regarding the relevance of TNM in the pathologic staging of NSCLC in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(9):1049–59.CrossRefPubMed
3.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A et al. eds.: AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 253–704.
4.
Agulló-Ortuño MT, López-Ríos F, Paz-Ares L. Lung cancer genomic signatures. J Thorac Oncol. 2010;5(10):1673–91.CrossRefPubMed
5.
Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006;24:1679–88.CrossRefPubMed
6.
Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol. 2008;26(6):877–83.CrossRefPubMed
7.
Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected NSCLC. J Clin Oncol. 2010;28(29):4417–24.CrossRefPubMedCentralPubMed
8.
Lu Y, Lemon W, Liu P-Y, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I NSCLC. PLoS Med. 2006;3(12):e467.CrossRefPubMedCentralPubMed
9.
Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, et al. An immune response enriched 72-gene prognostic profile for early-stage NSCLC. Clin Cancer Res. 2009;15(1):284–90.CrossRefPubMed
10.
Zhu CQ, Pintilie M, John T, Strumpf D, Shepherd FA, Der SD, et al. Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer. 2009;10(5):331–40.CrossRefPubMed
11.
Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage NSCLC. J Clin Oncol. 2007;25:5562–9.CrossRefPubMed
12.
Neumann J, Feuerhake F, Kayser G, Wiech T, Aumann K, Passlick B, et al. Gene expression profiles of lung adenocarcinoma linked to histopathological grading and survival but not to EGF-R status: a microarray study. BMC Cancer. 2010;10:77.CrossRefPubMedCentralPubMed
13.
Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegmanet P et al. Gene expression-based classification of NSCLC and survival prediction. PloS One 2010; 5(4): e10312.
14.
Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, Guedj M et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One 2010;22; 5(7):e11712.
15.
Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J et al. Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One 2010;17;5(8):e12222.
16.
Zhu CQ, Strumpf D, Li CY, Li Q, Liu N, Der S, et al. Prognostic gene expression signature for SCC of lung. Clin Cancer Res. 2010;16:5038.CrossRefPubMed
17.
Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, et al. A practical molecular assay to predict survival in resected non-squamous, NSCLC: development and international validation studies. Lancet. 2012;379:823–32.CrossRefPubMedCentralPubMed
18.
Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez Campos G, Calles A, Sanz-Ortega J, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer. 2012;12:260.CrossRefPubMedCentralPubMed
19.
Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, et al. Adjustment of systematic microarray data bases. Bioinformatics. 2003;20(1):105–14.CrossRef
20.
Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA. 2002;99(10):6567–72.CrossRefPubMedCentralPubMed
21.
Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131–135.
22.
23.
Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007;99(2):147–57.CrossRefPubMed
24.
Perez-Andres M, Paiva B, Nieto WG, Caraux J, Schmitz CA, Almeida J, et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom. 2010;78B(Suppl. 1):S47–60.CrossRef
25.
Tangye SG, Good KL. Human IgM+ CD27+ B cells: memory B cells or “memory” B cells? J Immunol. 2007;179(1):13–9.CrossRefPubMed
26.
White E. The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev. 2003;17(15):1813–6.CrossRefPubMed
27.
Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25(7):1182–8.
28.
Trinidad EM, Ballesteros M, Zuloaga J, Zapata A, Alonso-Colmenar LM. An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression. Blood. 2009;114(24):5081–90.CrossRefPubMed
29.
Shapiro MJ, Nguyen CT, Aghajanian H, Zhang W, Shapiro VS. Negative regulation of TCR signaling by linker for activation of X cells via phosphotyrosine-dependent and -independent mechanisms. J Immunology. 2008;181:7055–61.CrossRef
30.
Zikos AD, Donnenberg RJ, Landreneau JD, Luketich JD, Donnenberg VS. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in NSCLC. Cancer Immunol Immunother. 2011;60:819–27.CrossRefPubMedCentralPubMed
31.
Hagn M, Sontheimer K, Dahlke K, Brueggemann S, Kaltenmeier C, Beyer T, et al. Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunol Cell Biol. 2012;90(4):457–67.CrossRefPubMed
32.
Chen H-Y, Yu S-L, Chen C-H, Chang GC, Chen CY, Yuan A, et al. A five gene signature and clinical outcome in NSCLC. N Engl J Med. 2007;356:11–20.CrossRefPubMed
33.
Mahabeleshwar GH, Das R, Kundu GC. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of EGFR/extracellular signal regulated kinase pathways. J BiolChem. 2004;279:9733–42.
34.
Majolini MB, D’Elios MM, Galieni P, Boncristiano F, Lauria G, Del Prete JL, et al. Expression of the T-cell-specific tyrosine kinase lck in normal B-1 cells and in chronic lymphocytic leukemia B cells. Blood. 1998;91:3390–6.PubMed
35.
Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012;131(3):871–80.CrossRefPubMedCentralPubMed
36.
Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP, et al. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 2001;61(21):7889–99.PubMed
37.
Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol. 2005;175(4):2278–85.CrossRefPubMed
38.
Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1–4.CrossRefPubMedCentralPubMed
39.
Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, et al. Prognostic immune markers in NSCLC. Clin Cancer Res. 2011;17(16):5247–56.CrossRefPubMed
40.
Hernando F, Sanz J, Jarabo JR, et al. A new genetic signature defining two prognostic groups among patients with completely resected early non-small cell lung cancer. J Thor Oncol. 2012;7(6):S59.
41.
Sanz J, Hernandez S, Hernando F, Larriba JLG, Puente J, Ferrer M, et al. An intratumoral B-cell immune response determines favorable prognosis for early stage lung cancer and can be assessed by different immunoscores. Modern Pathol. 2013;26:466A.
Metadata
Title
A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer
Authors
S. Hernández-Prieto
A. Romera
M. Ferrer
J. L. Subiza
J. A. López-Asenjo
J. R. Jarabo
A. M. Gómez
Elena M. Molina
J. Puente
J. L. González-Larriba
F. Hernando
B. Pérez-Villamil
E. Díaz-Rubio
J. Sanz-Ortega
Publication date
01-04-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1235-1

Other articles of this Issue 4/2015

Clinical and Translational Oncology 4/2015 Go to the issue

Research Article

Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells

Research Article

Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity?

Clinical Guides in Oncology

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Research Article

Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma

Educational Series – Red Series

Preventive treatments for breast cancer: recent developments

Research Article

Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto’s thyroiditis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits